Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge has advised KLAR Partners in connection with its divestment of Swoosh Group to Serwent

Swoosh is a leading provider of inspection, maintenance, and services for underground infrastructure in Sweden, delivering sewer pipe inspection, cleaning, repair, and maintenance to municipalities, industrial operators, and property owners across 23 sites nationwide. Swoosh today employs approximately 450 people and generates revenues of nearly SEK 700 million.
August 13, 2026

Vinge has advised Montrose by Carnegie AB on its application for authorisation to conduct securities business

Vinge has successfully advised Montrose by Carnegie AB in connection with its application to the Swedish Financial Supervisory Authority for authorisation to conduct securities business. The authorisation was granted by the Swedish Financial Supervisory Authority on 2 July 2026.
August 12, 2026

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026